Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis
Yixuan Wang,Haojia Wang,Keyan Chai,Siyu Guo,Yifei Gao,Jiaqi Li,Chuanqi Qiao,Siyun Yang,Jiying Zhou,Yifan Lin,Xiaomeng Zhang,Jiarui Wu
DOI: https://doi.org/10.1097/md.0000000000038032
IF: 1.6
2024-05-26
Medicine
Abstract:Malignant pleural effusions (MPE) are characterized by the accumulation of fluid in the pleural space, resulting from lung cancer or other malignant tumors affecting the pleura, which is a frequently observed complication in advanced-stage malignancies. [ 1 ] In the case of MPE, more than 3-quarters of patients suffer from lung cancer or breast cancer, with metastatic adenocarcinoma being the most prevalent subtype in China. [ 2 , 3 ] Patients with MPE are often accompanied by symptoms such as chest tightness, palpitations, fever, shortness of breath, dry cough, and chest pain, which suggest a poor prognosis. [ 4 ] Currently, the commonly employed clinical treatment methods for pleural effusion include therapeutic thoracentesis, chemical pleurodesis, indwelling thoracic drainage tube, indwelling thoracic catheter combined with chemical pleurodesis, systemic anti-tumor therapy, etc. [ 5 ] Pleural effusion drainage combined with drug pleural perfusion is widely practiced in clinic due to its simplicity, minimal invasiveness, and reduced risk of individual complications. Cisplatin, a chemotherapeutic drug, has proven effective in managing pleural effusion. It can not only control the progression of cancer, but also induce inflammation and occlusion of pleural adhesion to control pleural effusion. However, cisplatin is highly toxic, and patients are prone to adverse reactions such as bone marrow suppression, gastrointestinal reactions, and liver function damage.
medicine, general & internal